02:38 PM EST, 01/14/2026 (MT Newswires) -- (Updates with the latest stock movement in the first paragraph and headline.)

ImmunityBio ( IBRX ) shares were up about 7% in recent Wednesday trading after the company said that Anktiva plus Bacillus Calmette-Guerin was approved by the Saudi Food and Drug Authority for the treatment of adult patients with non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease.

ImmunityBio ( IBRX ) said it plans to open a regional office in Saudi Arabia to support physicians and health systems across the Middle East and North Africa.

The company added it will collaborate with Biopharma Cigalah as its commercial and distribution partner in the region.

Enrollment for a randomized trial in BCG-naive patients comparing BCG alone to BCG plus Anktiva is on track to be completed by Q2, with a potential biologics license application submission by the end of the year, the company said.

Anktiva has been approved in the US and UK, and was granted conditional approval in the European Union.

Price: 3.02, Change: +0.20, Percent Change: +6.91